A Phase III, Randomized Study Assessing the Clinical Outcomes of Combining Erlotinib with Bevacizumab and Panitumumab Versus Erlotinib Alone as Second-Line Chemotherapy in Patients with Non-Small-Cell Lung Cancer (NSCLC)
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Panitumumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Mar 2018 New trial record